[
    [
        {
            "time": "2018-09-17",
            "original_text": "格隆汇港股聚焦(9.17)︱白云山子公司星群药业获药品GMP证书 腾讯控股耗资3770.48万港元回购11万股",
            "features": {
                "keywords": [
                    "白云山",
                    "星群药业",
                    "药品GMP证书",
                    "腾讯控股",
                    "回购"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(9.17)︱白云山子公司星群药业获药品GMP证书 腾讯控股耗资3770.48万港元回购11万股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-17",
            "original_text": "上海医药(02607.HK)控股股东上实集团增持10万股H股",
            "features": {
                "keywords": [
                    "上海医药",
                    "上实集团",
                    "增持"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(02607.HK)控股股东上实集团增持10万股H股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-17",
            "original_text": "投资医药主题，还在纠结创新药or仿制药？",
            "features": {
                "keywords": [
                    "医药主题",
                    "创新药",
                    "仿制药"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "投资医药主题，还在纠结创新药or仿制药？",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]